دورية أكاديمية
Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
العنوان: | Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML. |
---|---|
المؤلفون: | Kaushik S; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Liu F; Department of Biochemistry and Molecular Biology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA., Veazey KJ; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gao G; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Das P; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Neves LF; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lin K; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Cancer Epigenetics, Houston, TX, USA., Zhong Y; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Cancer Epigenetics, Houston, TX, USA., Lu Y; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Cancer Epigenetics, Houston, TX, USA., Giuliani V; Institute for Applied Cancer Science/Center for Co-clinical Trials, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bedford MT; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Cancer Epigenetics, Houston, TX, USA., Nimer SD; Department of Biochemistry and Molecular Biology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA.; Department of Medicine, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA., Santos MA; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Center for Cancer Epigenetics, Houston, TX, USA. |
المصدر: | Leukemia [Leukemia] 2018 Feb; Vol. 32 (2), pp. 499-509. Date of Electronic Publication: 2017 Jun 30. |
نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE |
أسماء مطبوعة: | Publication: 2000- : London : Nature Publishing Group, Specialist Journals Original Publication: [Baltimore, Md.] : Williams & Wilkins, [c1987- |
مواضيع طبية MeSH: | Antineoplastic Agents/*pharmacology , Histone-Lysine N-Methyltransferase/*genetics , Leukemia, Myeloid, Acute/*drug therapy , Leukemia, Myeloid, Acute/*genetics , Myeloid-Lymphoid Leukemia Protein/*genetics , Protein-Arginine N-Methyltransferases/*antagonists & inhibitors , Small Molecule Libraries/*pharmacology, Animals ; Cell Line, Tumor ; Disease Models, Animal ; Gene Deletion ; Gene Expression Regulation, Leukemic/drug effects ; Gene Expression Regulation, Leukemic/genetics ; Gene Rearrangement/drug effects ; Gene Rearrangement/genetics ; Mice ; Mice, Inbred NOD ; Mice, SCID ; Oncogene Proteins, Fusion/genetics |
مستخلص: | The hematological malignancies classified as mixed lineage leukemias (MLL) harbor fusions of the MLL1 gene to partners that are members of transcriptional elongation complexes. MLL-rearranged leukemias are associated with extremely poor prognosis, and response to conventional therapies and efforts to identify molecular targets are urgently needed. Using mouse models of MLL-rearranged acute myeloid leukemia, here we show that genetic inactivation or small-molecule inhibition of the protein arginine methyltransferase PRMT5 exhibit anti-tumoral activity in MLL-fusion protein-driven transformation. Genome-wide transcriptional analysis revealed that inhibition of PRMT5 methyltransferase activity overrides the differentiation block in leukemia cells without affecting the expression of MLL-fusion direct oncogenic targets. Furthermore, we find that this differentiation block is mediated by transcriptional silencing of the cyclin-dependent kinase inhibitor p21 (CDKN1a) gene in leukemia cells. Our study provides pre-clinical rationale for targeting PRMT5 using small-molecule inhibitors in the treatment of leukemias harboring MLL rearrangements. |
References: | Nat Rev Cancer. 2007 Nov;7(11):823-33. (PMID: 17957188) Hematology Am Soc Hematol Educ Program. 2011;2011:354-60. (PMID: 22160057) Nature. 2011 Oct 02;478(7370):529-33. (PMID: 21964340) Nat Cell Biol. 2009 May;11(5):652-8. (PMID: 19377467) Nature. 2006 Aug 17;442(7104):818-22. (PMID: 16862118) Mol Cell. 2014 Nov 20;56(4):564-79. (PMID: 25457166) Nat Biotechnol. 2015 Jun;33(6):661-7. (PMID: 25961408) Bioinformatics. 2015 Jan 15;31(2):166-9. (PMID: 25260700) Nat Commun. 2015 Jun 01;6:7140. (PMID: 26028225) Nat Struct Mol Biol. 2009 Mar;16(3):304-311. (PMID: 19234465) Cancer Cell. 2011 Jul 12;20(1):66-78. (PMID: 21741597) Cancer Cell. 2011 Jul 12;20(1):53-65. (PMID: 21741596) Nature. 2014 Oct 2;514(7520):107-11. (PMID: 25079327) Exp Hematol. 2011 Apr;39(4):473-485.e4. (PMID: 21288478) Mol Cell Biol. 2008 Oct;28(20):6262-77. (PMID: 18694959) Mol Cell Biol. 2004 Nov;24(21):9630-45. (PMID: 15485929) Cancer Cell. 2012 Apr 17;21(4):473-87. (PMID: 22464800) Nucleic Acids Res. 2009 Aug;37(15):4965-76. (PMID: 19528079) J Clin Invest. 2016 Oct 3;126(10):3961-3980. (PMID: 27643437) Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13516-21. (PMID: 23904475) Nature. 2015 Jul 2;523(7558):96-100. (PMID: 25970242) Cancer Cell. 2010 Oct 19;18(4):329-40. (PMID: 20951943) Genes Dev. 2009 Aug 1;23(15):1749-62. (PMID: 19584108) J Biol Chem. 2013 Dec 6;288(49):35534-47. (PMID: 24189068) Int J Hematol. 2010 Jun;91(5):735-41. (PMID: 20454944) Mol Cell. 2005 Apr 29;18(3):263-72. (PMID: 15866169) Cell Stem Cell. 2007 Sep 13;1(3):324-37. (PMID: 18371366) Nature. 2011 Aug 03;478(7370):524-8. (PMID: 21814200) Nat Cell Biol. 2007 Oct;9(10):1208-15. (PMID: 17891136) EMBO J. 2007 Aug 8;26(15):3558-69. (PMID: 17627275) Mol Cell Biol. 2010 Jun;30(11):2811-22. (PMID: 20368355) Cell Stem Cell. 2009 Feb 6;4(2):129-40. (PMID: 19200802) Genes Dev. 2010 Dec 15;24(24):2772-7. (PMID: 21159818) Genome Biol. 2010;11(10):R106. (PMID: 20979621) Cancer Discov. 2015 Mar;5(3):288-303. (PMID: 25582697) Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517) Nat Cell Biol. 2008 Dec;10(12):1431-9. (PMID: 19011621) Nat Chem Biol. 2015 Jun;11(6):432-7. (PMID: 25915199) J Clin Invest. 2015 Sep;125(9):3532-44. (PMID: 26258414) Sci Signal. 2011 Sep 13;4(190):ra58. (PMID: 21917714) Genome Biol. 2013 Apr 25;14(4):R36. (PMID: 23618408) Nucleic Acids Res. 2006 Jan 24;34(2):543-54. (PMID: 16434701) Nat Rev Cancer. 2013 Jan;13(1):37-50. (PMID: 23235912) Nat Cell Biol. 2011 Feb;13(2):174-81. (PMID: 21258366) Mol Cell. 2013 Oct 10;52(1):37-51. (PMID: 24076217) Nat Chem Biol. 2012 Jan 29;8(3):277-84. (PMID: 22286128) Blood. 2003 Oct 1;102(7):2395-402. (PMID: 12805060) Cancer Cell. 2016 Jan 11;29(1):32-48. (PMID: 26766589) J Clin Oncol. 2008 Oct 1;26(28):4603-9. (PMID: 18559876) Genes Dev. 2009 Apr 1;23(7):877-89. (PMID: 19339691) Oncogene. 2017 Jan 19;36(3):373-386. (PMID: 27270440) Cancer Res. 2010 May 1;70(9):3833-42. (PMID: 20406979) |
معلومات مُعتمدة: | P30 CA016672 United States CA NCI NIH HHS |
المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Oncogene Proteins, Fusion) 0 (Small Molecule Libraries) 149025-06-9 (Myeloid-Lymphoid Leukemia Protein) EC 2.1.1.319 (Prmt5 protein, mouse) EC 2.1.1.319 (Protein-Arginine N-Methyltransferases) EC 2.1.1.43 (Histone-Lysine N-Methyltransferase) EC 2.1.1.43 (Kmt2a protein, mouse) |
تواريخ الأحداث: | Date Created: 20170701 Date Completed: 20190102 Latest Revision: 20200306 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC5865447 |
DOI: | 10.1038/leu.2017.206 |
PMID: | 28663579 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1476-5551 |
---|---|
DOI: | 10.1038/leu.2017.206 |